Available to mentor
Dr. Keshamouni is an Associate Professor of Medicine, in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan. Research biologist, Ann Arbor VA Medical Center. Dr. Keshamouni obtained his Master’s (Biochemistry) from Osmania University, and Ph.D (Plant Photobiology) from University of Hyderabad, in Hyderabad, India. Moved to United States completed postdoctoral trainings at Indiana University, Wayne State University and University of Michigan. Started his own laboratory at University of Michigan in 2008 investigating cellular and molecular interactions in lung tumor microenvironment. He was named Parker B Francis Fellow, received American Cancer Society Research Scholar Award and American Lung Association Lung Cancer Discovery Award. He serves on several grant review committees of public and private foundations in US and Europe. He is the member of both Cancer Biology and Immunology graduate programs.
-
PhDUniversity of Hyderabad, Hyderabad, 1996
-
M.Sc. BiochemistryOsmania University, Hyderabad, 1989
-
Center MemberGlobal REACH
-
Center MemberRogel Cancer Center
-
Center MemberMM-PKUHSC Joint Institute
Dr. Keshamouni’s group is broadly interested in deciphering cellular and molecular interactions in the tumor microenvironment (TME) that contribute to tumor growth and metastasis. Areas under investigation are a) innate immune surveillance mechanisms mediated by NK cells, macrophages, complement system and TLR signaling, b) Engineering NK cells with chimeric antigen receptors for lung cancer therapy, and c) restoring tumor suppressive mechanisms of the cytokine TGF-, a master regulator of tumor-stromal interactions in the TME.
-
Katkam SK, Zolov S, Shield D, Chuikov S, Keshamouni VG. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 2364 - 2364.Journal ArticleAbstract 2364: Anti-CADM1 chimeric antigen receptor (CAR) is a novel therapeutic strategy against small cell lung cancer
DOI:10.1158/1538-7445.am2024-2364 -
Zou Y, Ball H, Harris C, Ramnath N, Keshamouni V, Nagrath S. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 2589 - 2589.Journal ArticleAbstract 2589: Novel workflow to generate natural killer cell sensitivity prediction model based on the epithelial mesenchymal transition related reprogramming at a single cell resolution
DOI:10.1158/1538-7445.am2024-2589 -
Winkler A, Listunov D, Linhares B, Ray J, Weaver S, Zolov S, Keshamouni V, Grembecka J, Cierpicki T. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 3239 - 3239.Journal ArticleAbstract 3239: Targeting the GAS41 YEATS domain in non-small cell lung cancer with novel small molecules
DOI:10.1158/1538-7445.am2024-3239 -
Zolov S, Chuikov S, Katkam SK, Shield D, Keshamouni VG. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 6360 - 6360.Journal ArticleAbstract 6360: A novel CAR-NK cell therapy to target lung adenocarcinoma cells
DOI:10.1158/1538-7445.am2024-6360 -
Keshamouni V. 2024 Mar 20;PresentationHost Patrolling Against Tumor Metastasis and the Promise of CARs
-
Moore BB, Ballinger MN, Bauer NN, Blackwell TS, Borok Z, Budinger GRS, Camoretti-Mercado B, Erzurum SC, Himes BE, Keshamouni VG, Kulkarni HS, Mallampalli RK, Mariani TJ, Martinez FJ, McCombs JE, Newcomb DC, Johnston RA, O'Reilly MA, Prakash YS, Ridge KM, Sime PJ, Sperling AI, Violette S, Wilkes DS, Königshoff M. Ann Am Thorac Soc, 2023 Aug; 20 (8): 1077 - 1087.Journal ArticleBuilding Career Paths for Ph.D., Basic and Translational Scientists in Clinical Departments in the United States: An Official American Thoracic Society Workshop Report.
DOI:10.1513/AnnalsATS.202304-305ST PMID: 37526479 -
Keshamouni V. 2022 Nov 1;PresentationImmunological Consequences of EMT in Lung Cancer
-
Keshamouni V. 2022 Nov 1;PresentationPulmonary Research Conference. " Implications of Epithelial-mesenchymal Transitions for Tumor Immune Surveillance",